Table 2.
Concomitant medication use
| Treatment | Baseline biologic experience | All patients n = 1912 | |
|---|---|---|---|
| Biologic naïve n = 1073 | Biologic exposed n = 839 | ||
| DMARDs, n (%) | 812 (75.7) | 541 (64.5) | 1353 (70.8) |
| Methotrexate | |||
| Baseline, n (%) | 553 (51.5) | 361 (43.0) | 914 (47.8) |
| Dose at baseline, mean (SD), g | 13.6 (4.7) | 15.6 (5.4) | 14.4 (5.1) |
| Month 6, n (%) | 375 (34.9) | 272 (32.4) | 647 (33.8) |
| Dose at month 6, mean (SD), g | 13.8 (4.9) | 15.3 (5.3) | 14.5 (5.1) |
| Corticosteroids | |||
| Baseline, n (%) | 410 (38.2) | 386 (46.0) | 796 (41.6) |
| Dose at baseline, mean (SD), ga | 8.8 (5.6) | 8.1 (5.1) | 8.5 (5.4) |
| Month 6, n (%) | 309 (28.8) | 306 (36.5) | 615 (32.2) |
| Dose at month 6, mean (SD), ga | 7.6 (4.6) | 7.7 (5.2) | 7.7 (4.9) |
DMARD disease-modifying antirheumatic drug
aPrednisone equivalent